What was BOSTON SCIENTIFIC CORP's revenue in fiscal 2025?

BOSTON SCIENTIFIC CORP reported revenue of $20.07B for fiscal 2025, up 19.9% from fiscal 2024.

What is BOSTON SCIENTIFIC CORP's net margin?

Operating margin was 18.0% and net margin was 14.4%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

What is BOSTON SCIENTIFIC CORP's diluted EPS?

Diluted EPS was $1.94, up 55.2% from the prior year.

Are BOSTON SCIENTIFIC CORP insiders buying or selling shares?

Over the past 12 months, insiders reported 4 open-market purchases totalling $554.0K and 9 open-market sales totalling $24.3M on Form 4.

Which institutions hold BOSTON SCIENTIFIC CORP stock?

2,146 institutions reported holding BOSTON SCIENTIFIC CORP shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Overview

BOSTON SCIENTIFIC CORP

BSXNYSEHealth CareSurgical & Medical Instruments & ApparatusCIK 0000885725S&P 500

Latest 10-K: FY2025, filed Feb 17, 2026 · Open the 10-K (Inline XBRL) ↗

Ask about BSX in Workspace

Revenue: $20.07B; 19.9%YoYup from FY2024; TotalRevenue
Gross profit: $13.85B; 20.6%YoYup from FY2024; GrossProfit
Operating income: $3.61B; 38.8%YoYup from FY2024; OperatingIncome
Net income: $2.90B; 56.4%YoYup from FY2024; NetIncome
Diluted EPS: $1.94; 55.2%YoYup from FY2024; EPSDiluted
Diluted shares: 1.49B; 0.6%YoYup from FY2024; WeightedAvgSharesDiluted

At a glance

Growth

BOSTON SCIENTIFIC CORP reported revenue of $20.07B for fiscal 2025, up 19.9% from fiscal 2024.
Revenue grew faster than the median S&P 500 member in 4 of the last 5 fiscal years.

Profitability

Operating margin was 18.0% and net margin was 14.4%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Per share

Diluted EPS was $1.94, up 55.2% from the prior year.

Insiders & holders

Over the past 12 months, insiders reported 4 open-market purchases totalling $554.0K and 9 open-market sales totalling $24.3M on Form 4.
2,146 institutions reported holding BOSTON SCIENTIFIC CORP shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 23, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was BOSTON SCIENTIFIC CORP's revenue in fiscal 2025?: BOSTON SCIENTIFIC CORP reported revenue of $20.07B for fiscal 2025, up 19.9% from fiscal 2024.
What is BOSTON SCIENTIFIC CORP's net margin?: Operating margin was 18.0% and net margin was 14.4%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is BOSTON SCIENTIFIC CORP's diluted EPS?: Diluted EPS was $1.94, up 55.2% from the prior year.
Are BOSTON SCIENTIFIC CORP insiders buying or selling shares?: Over the past 12 months, insiders reported 4 open-market purchases totalling $554.0K and 9 open-market sales totalling $24.3M on Form 4.
Which institutions hold BOSTON SCIENTIFIC CORP stock?: 2,146 institutions reported holding BOSTON SCIENTIFIC CORP shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Vanguard Capital Management's.

Data as of Oct 23, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: S&P 500 median change. Line under a label: how many S&P 500 companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Revenue	$20.07B19.9%up S&P 500 6.4%	$16.75B17.6%up S&P 500 4.5%	$14.24B12.3%up S&P 500 4.8%	$12.68B6.7%up S&P 500 10.3%	$11.89B19.9%up S&P 500 13.8%	14.0% S&P 500 6.6%
Gross Profit Median of 315 / 498	$13.85B20.6%up S&P 500 6.8%	$11.49B16.1%up S&P 500 5.5%	$9.90B13.4%up S&P 500 5.2%	$8.73B6.7%up S&P 500 8.3%	$8.18B26.8%up S&P 500 15.7%	14.1% S&P 500 6.2%
Operating Income Median of 373 / 498	$3.61B38.8%up S&P 500 7.3%	$2.60B11.1%up S&P 500 7.4%	$2.34B42.1%up S&P 500 4.9%	$1.65B37.5%up S&P 500 7.5%	$1.20Bn/m S&P 500 23.5%	31.8% S&P 500 7.2%
Net Income	$2.90B^§56.4%up S&P 500 4.8%	$1.85B^§18.0%up S&P 500 5.7%	$1.57B^§144.5%up S&P 500 1.9%	$0.64B^§34.8%down S&P 500 1.3%	$0.98B^§n/m S&P 500 33.9%	31.0% S&P 500 4.1%
EPS (Diluted)	$1.9455.2%up S&P 500 6.2%	$1.2516.8%up S&P 500 7.9%	$1.07137.8%up S&P 500 1.9%	$0.4534.8%down S&P 500 1.5%	$0.69n/m S&P 500 34.8%	29.5% S&P 500 5.6%

§ Net income available to common stockholders; the company files no net-income line.

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: S&P 500 median change. Line under a label: how many S&P 500 companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Total Assets	$43.67B10.9%up S&P 500 5.6%	$39.40B12.1%up S&P 500 3.4%	$35.14B8.2%up S&P 500 4.1%	$32.47B0.7%up S&P 500 2.2%	$32.23B4.7%up S&P 500 6.7%	7.9% S&P 500 4.7%
Total Liabilities Median of 357 / 498	—	—	—	—	—	— S&P 500 4.4%
Stockholders' Equity	$24.47B11.2%up S&P 500 6.8%	$22.00B12.7%up S&P 500 5.4%	$19.53B11.1%up S&P 500 7.3%	$17.57B5.7%up S&P 500 2.5%	$16.62B8.5%up S&P 500 9.0%	10.2% S&P 500 6.1%
Cash & Equivalents	$1.97B374.6%up S&P 500 5.2%	$0.41B52.1%down S&P 500 1.9%	$0.86B6.8%down S&P 500 6.7%	$0.93B51.8%down S&P 500 -8.6%	$1.93B11.0%up S&P 500 -2.9%	0.5% S&P 500 2.0%
Total Debt Median of 393 / 498	$11.44B^†6.4%up S&P 500 2.3%	$10.75B18.1%up S&P 500 0.1%	$9.10B1.9%up S&P 500 0.1%	$8.94B1.4%down S&P 500 0.1%	$9.06B0.9%down S&P 500 0.0%	6.0% S&P 500 3.7%

† Sum of short-term and long-term debt; the company files no total-debt line.

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: S&P 500 median change. Line under a label: how many S&P 500 companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Operating Cash Flow	$4.53B32.0%up S&P 500 6.3%	$3.44B37.2%up S&P 500 4.8%	$2.50B64.0%up S&P 500 9.9%	$1.53B18.4%down S&P 500 -0.7%	$1.87B24.0%up S&P 500 10.7%	24.8% S&P 500 7.0%
Capital Expenditures	$876.00M10.9%up S&P 500 5.4%	$790.00M11.1%up S&P 500 2.8%	$711.00M20.9%up S&P 500 11.3%	$588.00M6.1%up S&P 500 14.0%	$554.00M47.3%up S&P 500 8.1%	12.1% S&P 500 9.0%
Free Cash Flow Median of 378 / 498	$3.66B38.3%up S&P 500 7.3%	$2.65B47.6%up S&P 500 6.1%	$1.79B91.0%up S&P 500 8.8%	$0.94B28.7%down S&P 500 -11.3%	$1.32B16.3%up S&P 500 10.2%	29.1% S&P 500 4.9%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

S&P 500 median = median of the companies in the index on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-20. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2025

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

2.0%

Wall Street

on net earnings

FY2024 1.4%

2.6%

Value investor

on free cash flow

FY2024 2.0%

Gap +0.6 pts: Value-investor figure 0.6 points higher

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E 49.1×

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: $4.53B
Capex: $876.00M
Free cash flow: $3.66B
R&D: $2.05B
Buybacks: —
Dividends: —
Debt repaid: $1.59B
Debt issued: —
Net debt change: —

Uses of operating cash flow, FY2025

Capex19.3%
Debt repayment35.2%

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21$1.32B
FY22$938.00M
FY23$1.79B
FY24$2.65B
FY25$3.66B

Buybacks by year

FY21$0.00
FY22$0.00
FY23—
FY24—
FY25—

Smart money

Who is trading and holding BOSTON SCIENTIFIC CORP, from Form 4, 13F and 13D/13G filings.

Insiders

Insider activity · past 12 months

Open-market trades reported on Form 4 in the past 365 days.

Buys: 4; 3 insiders
Sales: 9; 4 insiders
Value sold: $24.3M
Shares sold: 253,996
Net shares: -244,196; bought minus sold
Last trade: May 20, 2026

Purchases 2% of valueSales 98% of value

Latest open-market insider trades from Form 4
Insider	Type	Date	Shares	Price	Value	Filing
LUDWIG EDWARD JDirector	Buy	May 20, 2026	3,580	$56.68	$202,914	View filing on SEC EDGAR
Pegus CherylDirector	Buy	May 20, 2026	1,770	$56.49	$99,987	View filing on SEC EDGAR
Habiger David CDirector	Buy	May 20, 2026	2,250	$55.92	$125,820	View filing on SEC EDGAR

See plans

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders

13F

Quarter ended Jun 30, 2026; change versus Mar 31, 2026.

Institutions reporting: 2,146
Top 3 hold: 11.2%; of 1.49B diluted shares, FY2025 10-K

Top 3 holders, share of diluted sharesof 100%

Vanguard Capital Management6.5%
97,087,553 sh · $4.1BAdded 0.7%13F-HR · Jun 30, 2026 on SEC EDGAR
STATE STREET CORP4.7%
70,111,196 sh · $3.0BAdded 3.1%13F-HR · Jun 30, 2026 on SEC EDGAR
Banque Cantonale Vaudoise0.0%
67,611 sh · $2.9BNo prior-quarter match13F-HR · Jun 30, 2026 on SEC EDGAR

See plans

Some filers' amendments could not be read, so a few holders may be counted twice.

Bars: share of diluted shares on a shared scale; the tick marks 5%. 13F filings are due 45 days after quarter end, so this is the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over

13D/G

SC 13D / 13G, latest filing per filer.

Filers at 5%+: 2
Combined: 15.1%; sum of latest filings
Activist (13D): 0

5%+ filers, share of the class as filedof 100%

BlackRock, Inc.7.6%
Passive · 13GLast filed 1 yr agoSC 13G/A · Apr 17, 2025 on SEC EDGAR
Vanguard Capital Management7.47%
Passive · 13GSC 13G · Apr 29, 2026 on SEC EDGAR

No filer switched from a passive 13G to an activist 13D in the last 365 days.

Percent of the class as each filer last reported it; filings older than a year may no longer reflect the stake. Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers BOSTON SCIENTIFIC CORP later changed — same XBRL tag, both filings linked.

numbers changed: 6
restating filings: 3
came with an amendment or a non-reliance notice: 4

Mar 31, 1999 · 10-K/A
changed 4 numbers
Amended filing
Open filing
- Net incomeQ2 1996$22.5M restated to $15.3M−32.2%
  As reported · Aug 14, 1996fds5:NET-INCOMEAny P/E built on the original was 47.4% too low.
- Net incomeQ2 1997$48.5M restated to $35.3M−27.2%
  As reported · Aug 14, 1997fds5:NET-INCOMEAny P/E built on the original was 37.4% too low.
- Pretax incomeQ2 1997$89.5M restated to $69.8M−22.1%
  As reported · Aug 14, 1997fds5:INCOME-PRETAX
- Net incomeFY 1997$139.3M restated to $110.4M−20.8%
  As reported · Mar 31, 1998fds5:NET-INCOMEAny P/E built on the original was 26.2% too low.
Oct 29, 2018 · 10-Q
changed 1 number
No amendment filed
Open filing
- Operating cash flowQ3 2017$554M restated to $742M+33.9%
  As reported · Nov 2, 2017us-gaap:NetCashProvidedByUsedInOperatingActivitiesAny P/OCF built on the original was 25.3% too high.
Feb 19, 2019 · 10-K
changed 1 number
No amendment filed
Open filing
- Operating cash flowFY 2016$972M restated to $1.2B+21.6%
  As reported · Feb 23, 2017us-gaap:NetCashProvidedByUsedInOperatingActivitiesAny P/OCF built on the original was 17.8% too high.

BSX is not the only one.

See every restatement we've found across the market — or get an alert the next time BSX revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of BOSTON SCIENTIFIC CORP's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BSX's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

UNITEDHEALTH GROUP INC

MRK· Health Care

Merck & Co., Inc.

TMO· Health Care

THERMO FISHER SCIENTIFIC INC.

ABT· Health Care

ABBOTT LABORATORIES

ISRG· Health Care

INTUITIVE SURGICAL INC

AMGN· Health Care

AMGEN INC

Recent SEC filings

The six newest, periodic reports and 8-Ks together. Dates are SEC filing dates.

All filings on EDGAR

Six most recent SEC filings, newest first
Form	Filing	Filed	Document
8-K	Current report (material events) · Event dated Oct 1, 2026 0000885725-26-000064 · accepted 10:11 UTC	Oct 7, 2026	Open	Filed Oct 7, 2026 · 0000885725-26-000064
8-K	Current report (material events) · Event dated Sep 21, 2026 0000885725-26-000061 · accepted 10:01 UTC	Sep 23, 2026	Open	Filed Sep 23, 2026 · 0000885725-26-000061
10-Q	Quarterly report · Quarter ended Jun 30, 2026 0000885725-26-000053 · accepted 10:32 UTC	Aug 3, 2026	Open	Filed Aug 3, 2026 · 0000885725-26-000053
10-K	Annual report · Fiscal year ended Dec 31, 2025 0000885725-26-000010 · accepted 21:08 UTC	Feb 17, 2026	Open	Filed Feb 17, 2026 · 0000885725-26-000010
10-K/A	Annual report amendment · Fiscal year ended Dec 31, 2023 0000885725-24-000020 · accepted 21:47 UTC	Feb 21, 2024	Open	Filed Feb 21, 2024 · 0000885725-24-000020
10-Q/A	Quarterly report amendment · Quarter ended Mar 31, 2013 0000885725-13-000015 · accepted 20:01 UTC	May 7, 2013	Open	Filed May 7, 2013 · 0000885725-13-000015

“Open” goes to the Inline XBRL viewer when the filing has one, else the primary document. The accession opens the EDGAR index.

Research Reports

No published research on BSX yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on BSX and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

27 tables, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 120.5Mrows
ratio: 5.3Mrows
filing: 2.35Mrows
entity: 19,888rows

292 standard concepts.

Built from these SEC forms

10-K
10-K/A
10-K405
10-KT
10-Q
10-Q/A
10-QT
20-F
20-F/A
40-F
40-F/A
8-K
8-K/A
6-K
6-K/A
S-1
S-3
S-4
S-11
F-1
F-3
F-4
POS AM
10-KSBsoon
10-QSBsoon
DEF 14Asoon
DEF 14Csoon
DEFA14Asoon
PRE 14Asoon
DEFM14Asoon
425soon
SC TO-Tsoon
SC TO-Isoon
SC 14D9soon
SC 13E3soon
CORRESPsoon
NT 10-Ksoon
NT 10-Qsoon
NT 20-Fsoon
N-PORT-Psoon

Smart money

Insider and institutional filings.

institutional_holding: 59.5Mrows
insider_transaction: 11.4Mrows
insider_filing: 5.2Mrows
insider_ownership: 1.33Mrows

78M+ smart-money rows in all.

Built from these SEC forms

Form 3
Form 3/A
Form 4
Form 4/A
Form 5
Form 5/A
13F-HR
13F-HR/A
13F-NT
13F-NT/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
Form 144
Form 144/A

One real fact row for BOSTON SCIENTIFIC CORP

Fact receiptOperatingCashFlow

Operating cash flow · FY2025

$4.53B

4,534,000,000 USD

BOSTON SCIENTIFIC CORP reported Operating cash flow of $4.5B for fiscal year 2025 in its 10-K filed Feb 17, 2026.

Fiscal period: 2025 FY
Period end: 2025-12-31
Form: 10-K
Filed: Feb 17, 2026
Entity (CIK): 0000885725

Provenance trail

Filed with the SEC
Form 10-K, filed Feb 17, 2026.
Accession 0000885725-26-000010
Open in the Inline XBRL viewer for 0000885725-26-000010
Reported in the filing
Operating cash flow for fiscal year 2025, the period ended 2025-12-31, in USD. Valuein maps the filed line to the standard concept OperatingCashFlow.
Stored as one fact row
Every channel returns this row with the same id.
fact_id 15d9c1faedea089185cf12b3df37b83bd4e09eabccac3afcb7951f6534d0b332
Shown on this page
The same $4.53B appears in the Cash Flow Statement and in Cash & capital allocation.

fact rowjson

{  "entity_id": "0000885725",  "standard_concept": "OperatingCashFlow",  "fiscal_year": 2025,  "fiscal_period": "FY",  "period_end": "2025-12-31",  "numeric_value": 4534000000,  "unit": "USD",  "accession": "0000885725-26-000010",  "fact_id": "15d9c1faedea089185cf12b3df37b83bd4e09eabccac3afcb7951f6534d0b332"}

Get the same data

Get your free API key

bash

# Fact-level Parquet over HTTPS, every row traced to its filingcurl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0000885725.parquet \  -o bsx.parquet

Read the API docs

Terminalbash

# The same tables in your notebooks and backtests; the free sample needs no token$ pip install valuein-sdk

Python

from valuein_sdk import ValueinClient with ValueinClient() as client:    sql = """        SELECT fiscal_year, numeric_value FROM fact        WHERE entity_id = '0000885725'          AND standard_concept = 'TotalRevenue'          AND fiscal_period = 'FY'    """    print(client.run_query(sql))

Install the SDK

bash

# Connect Claude or ChatGPT to the same facts, each with a fact_idhttps://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals BSX   # CIK 0000885725

Connect the MCP server

bash

# Ask in plain English; every figure comes back cited to its filingTell me about BSX: a quick, cited overview I can dig into.

Open BSX in Workspace

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 23, 2026. Canonical address: https://valuein.biz/data/BSX

APA-style text

Valuein. (2026, October 23). BOSTON SCIENTIFIC CORP (BSX) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/BSX

BibTeX

@misc{valuein_bsx_2026,
  author = {{Valuein}},
  title = {BOSTON SCIENTIFIC CORP (BSX) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/BSX}},
  note = {Data as of 2026-10-23; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 17, 2026 · accession 0000885725-26-000010

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View BSX filings on SEC EDGAR

At a glance

Growth

Profitability

Per share

Insiders & holders

02Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & valuation

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Smart money

Mar 31, 1999 · 10-K/A

Oct 29, 2018 · 10-Q

Feb 19, 2019 · 10-K

06Peers, filings & research

Sector Peers

Recent SEC filings

Research Reports

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for BOSTON SCIENTIFIC CORP

Provenance trail

Get the same data

08Cite this page

Insiders & holders

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Mar 31, 1999 · 10-K/A

Oct 29, 2018 · 10-Q

Feb 19, 2019 · 10-K

Sector Peers

Recent SEC filings

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for BOSTON SCIENTIFIC CORP

Provenance trail

Get the same data

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page